Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG)

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1365-1373

  Mackay, Helen J ^a   Gallinger, Steven ^a   Tsao, Ming S ^a   McLachlin, C Meg ^b   Tu, Dongsheng ^c   Keiser, Katharina ^d   Eisenhauer, Elizabeth A ^c   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c Queen's Cancer Research Institute   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Endometrial cancer; MSI; Prognostic factor; PTEN

Indexed keywords

ERLOTINIB; LETROZOLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMSIROLIMUS; MICROSATELLITE DNA; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; CANCER STAGING; CONFIDENCE INTERVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY;

AGED; CARCINOMA, ENDOMETRIOID; CONFIDENCE INTERVALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PTEN PHOSPHOHYDROLASE; KAPLAN-MEIER ESTIMATE;

EID: 77951667289     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.031     Document Type: Article

References (32)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
2. Kendrick J.E., and Huh W.K. Treatment considerations in advanced endometrial cancer. Curr Oncol Rep 9 (2007) 494-498
3. Llobet D, Palleres J, Yeramian A, et al. Molecular pathology of endometrial cancer: practical aspects from the diagnostic and therapeutical view points. J Clin Pathol 2008 [Epub ahead of print].
4. Lynch H.T., and de la Chapelle A. Hereditary colorectal cancer. New Engl J Med 348 (2003) 919-932
5. Peltomaki P. Deficient DNA mismatch repair. A common etiologic factor for colon cancer. Human Mol Genet 10 (2001) 735-740
6. Gryffe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. New Engl J Med 342 (2000) 69-77
7. Ribic C.M., Sargent D.J., Moore M.J., et al. Microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl J Med 349 (2006) 247-257
8. Lawes D.A., SenGupta S., and Boulos P.B. The clinical importance of microsatellite instability in sporadic cancer. Eur J Surg Oncol 29 (2003) 201-212
9. Black D., Soslow R.A., Levine D.A., et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial cancer. J Clin Oncol 11 (2006) 1745-1753
10. Zighelboim I., Goodfellow P.J., Gao F., et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of endometrioid type. J Clin Oncol 25 (2007) 2042-2048
11. Caduff R.F., Johnston C.M., Svoboda-Newman S.M., et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148 (1996) 1671-1678
12. Tibiletti M.G., Furlan D., Taborelli M., et al. Microsatellite instability in endometrial cancer: relation to histological subtypes. Gynecol Oncol 73 (1999) 247-252
13. Basil J.B., Goodfellow P.J., Rader J.S., et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89 (2000) 1758-1764
14. MacDonald N.D., Salvesen H.B., Ryan A., et al. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 60 (2000) 1750-1752
15. Fiumicino S., Ercoli A., Ferrandina G., et al. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol 19 (2001) 1008-1014
16. Muresu R., Sini M.C., Cossu A., et al. Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. Eur J Cancer 38 (2002) 1802-1809
17. An H.J., Kwang I.K., Kim J.Y., et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 31 (2005) 846-853
18. Athanassiadou P., Athanassiades D., Grapsa D., et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 17 (2007) 697-704
19. Salvesen H.B., Stefansson I., Kretzschmar E.I., et al. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25 (2004) 1615-1623
20. Kanamori Y., Kigawa J., Itamochi H., et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing post operative chemotherapy. Int J Cancer 100 (2002) 686-689
21. Steinbakk A, Skaland I, Gudlaugsson E, et al. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage I and II endometrioid type endometrial cancer. Am J Obstet Gynaecol 2009;200:1-78 [Epub].
22. Bilbao C., Dodriguez G., Ramirez R., et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 119 (2006) 563-570
23. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137-46.
24. Ma B.B., Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14 (2004) 650-658
25. Oza A.M., Eisenhauer E.A., Elit L., et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: IND-148. J Clin Oncol 26 (2008) 4319-4325
26. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160. J Clin Oncol 2006;24(18S):3003 [ASCO Proc ASCO, abs].
27. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial pre disposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
28. Peiffer S.L., Herzog T.J., Tribune D.J., et al. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 55 (1995) 1922-1926
29. Wong Y.F., Cheung T.H., Lo K.W., et al. Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel markers. Carcinogenesis 27 (2006) 951-955
30. Bennetot C., Buhard O., Jourdan F., et al. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening. Int J Cancer 113 (2005) 446-450
31. Rena Y., Liua X., Mab D., et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet 175 (2007) 107-116
32. Bussaglia E., del Rio E., Matias-Gulu X., et al. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Human Pathol 31 (2000) 312-317